Esperion Therapeutics Inc (ESPR) Stock Analysis

Esperion Therapeutics Inc (ESPR) is a publicly traded company in the HEALTHCARE sector. It trades at $3.13, carries a market capitalization of $805.76M. This page summarizes the public market data, fundamentals, and frequently asked questions for ESPR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Esperion Therapeutics Inc currently has a Neutral sentiment score of -0.01.

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on delivering innovative therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Headquartered in Ann Arbor, Michigan, Esperion is committed to transforming the treatment landscape for cardiovascular disease by developing and commercializing novel lipid-lowering agents. With a robust pipeline and a strong emphasis on patient-centered solutions, the company is well-positioned to play a significant role...

GNG Research Analysis

GNG Research scores Esperion Therapeutics Inc (ESPR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ESPR.

Frequently Asked Questions

Does ESPR pay dividends?

Esperion Therapeutics Inc (ESPR) does not currently pay a regular dividend.

What is ESPR's market cap?

Esperion Therapeutics Inc (ESPR) has a market capitalization of $805.76M with a current stock price of $3.13.